Substitutedaryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors

Details for Australian Patent Application No. 2009204358 (hide)

Owner Allergan, Inc.

Inventors Bhat, Smita S.; Heidelbaugh, Todd M.; Sinha, Santosh C.; Chow, Ken; Garst, Michael E.

Agent Davies Collison Cave

Pub. Number AU-A-2009204358

PCT Pub. Number WO2009/089132

Priority 11/971,829 09.01.08 US

Filing date 5 January 2009

Wipo publication date 16 July 2009

International Classifications

C07D 233/58 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings

A61K 31/4164 (2006.01) - 1,3-Diazoles

A61K 31/4427 (2006.01) - containing further heterocyclic ring systems

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

C07D 233/64 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings

C07D 401/06 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

29 July 2010 PCT application entered the National Phase

  PCT publication WO2009/089132 Priority application(s): WO2009/089132

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009204360-Methods for measuring a patint response upon administration of a drug and compositions thereof

2009204346-Genetic markers of mental illness